NEW YORK (GenomeWeb) – Kailos Genetics said today that it has received a strategic investment from In-Q-Tel, a nonprofit that invests in technologies to support the mission of the US intelligence community.

Terms and financial details of the deal were not disclosed.

Kailos said it plans to use the investment in a partnership with In-Q-Tell to develop its next-generation sequencing laboratory and software for the benefit of the intelligence community.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Dec
05
Sponsored by
Agilent

This webinar will discuss a molecular barcode-based error correction method that enables combined mutation detection and DNA copy number profiling through circulating tumor DNA sequencing.